SCHEMBL14949259

SCHEMBL14949259

Cc1cccc(Nc2nnc(-c3ccc(Oc4ccnc(N)n4)cc3)o2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.46
TP53 P04637 2/20 0.46
RAB9A P51151 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MEN1 O00255 1/20 0.46
MAPK1 P28482 1/20 0.46
KMT2A Q03164 1/20 0.46
GSK3B P49841 10/20 0.46
ACHE P22303 2/20 0.43
FLT1 P17948 3/20 0.43
KDR P35968 3/20 0.43
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.40
POLB P06746 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
MAPT P10636 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
ROCK1 Q13464 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12057527 0.87 NPC1 (0.47) NPC1TP53RAB9ASMN1; SMN2MEN1
SCHEMBL12336275 0.86 KDR (0.51) GSK3BFLT1KDRKDM4EFLT4
SCHEMBL14949194 0.84 NPC1 (0.48) NPC1TP53RAB9ASMN1; SMN2MEN1
SCHEMBL14949249 0.83 NPC1 (0.47) NPC1TP53RAB9ASMN1; SMN2MEN1
SCHEMBL14949189 0.81 MEN1 (0.54) NPC1TP53RAB9ASMN1; SMN2MEN1
SCHEMBL14949188 0.80 MEN1 (0.46) NPC1TP53RAB9ASMN1; SMN2MEN1
SCHEMBL13547695 0.80 PDGFRB (0.50) NPC1TP53RAB9ASMN1; SMN2MEN1
SCHEMBL14949192 0.80 MEN1 (0.48) NPC1TP53RAB9ASMN1; SMN2MEN1
SCHEMBL16786021 0.79 KDM4E (0.44) NPC1TP53RAB9ASMN1; SMN2MEN1
SCHEMBL14949256 0.78 ROCK1 (0.39) NPC1RAB9AMEN1KMT2AFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160096824-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2016-04-07 US disclosed
US-9212151-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-12-15 US disclosed
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2015-06-11 US disclosed
US-8957216-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-02-17 US disclosed
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION AMITECH THERAPEUTIC SOLUTIONS INC (US) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION MAP4K2, MAP3K20, MAP3K19 NPC1 3866/4885TP53 822/4885RAB9A 1281/4885
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition MAP4K2, MAP3K20, MAP3K19 NPC1 3866/4885TP53 822/4885RAB9A 1281/4885
US-20160096824-A1 Heterocyclic Compounds Useful for Kinase Inhibition MAP4K2, MAP3K20, MAP3K19 NPC1 3866/4885TP53 822/4885RAB9A 1281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.